Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>News>This Article

MRC and AstraZeneca Scoop Prestigious SCRIP Award

Published: Tuesday, December 04, 2012
Last Updated: Tuesday, December 04, 2012
Bookmark and Share
The innovative collaboration between the Medical Research Council and AstraZeneca has won the ‘Best Partnership Alliance’ award at the annual SCRIP Awards.

The AZ-MRC alliance broke new ground in the way industry collaborates with academia and government to share knowledge and discover and develop new drugs.

Clive Morris, AstraZeneca Vice President, New Opportunities iMed, said:

“We are deeply honoured that our alliance with the MRC has been singled out for its innovative character. This is especially meaningful because our alliance with the MRC has played a leading role in inspiring a new era of collaboration and open innovation in the industry.”

Dr Chris Watkins, Head of Translational Research and Industry Liaison at the MRC, who accepted the award, said:

"It's been an absolute pleasure to work with AstraZeneca throughout our ground-breaking compound collaboration and we feel we've made a real step forward in the way we collaborate with industry. We were really pleased with the quality of science we funded through the partnership and to have this all recognised by a prestigious SCRIP award is the icing on the cake, we're delighted to have won."

SCRIP is one of the world’s leading pharmaceutical and biotech news organisations and its ‘Best Partnership Alliance’ award recognises the importance of partnerships involving pharmaceutical and/or biotech companies in developing novel therapeutics.

The ceremony, which took place on 28 November at London’s Lancaster Hotel, rewarded excellence over the whole range of industry activities, from pharma, biotech and those companies that support them.

The AZ-MRC alliance, in which 22 previously studied AstraZeneca compounds were made available to academic researchers, was announced in December 2011. Since then, the MRC and AstraZeneca have announced £7 million funding for 15 research projects involving those compounds.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

MRC Laboratory of Molecular Biology Alumni Awarded Nobel Prize for Chemistry
Professor Michael Levitt, Professor Arieh Warshel and Professor Martin Karplus awarded the 2013 Nobel Prize in Chemistry.
Monday, October 14, 2013
MRC Delivering on the Life Sciences Strategy, One Year On
The Medical Research Council has made significant progress in implementing the measures outlined in last year’s Strategy for UK Life Sciences, according to a progress update published by the Government.
Tuesday, December 11, 2012
Medical Research Council Technology and Pharmidex Announce Drug Discovery Collaboration
Pharmidex to provide all in vivo ADME/PK drug discovery support to the MRCT in 2010.
Thursday, April 15, 2010
Scientific News
Drug May Prevent Life-Threatening Muscle Loss in Advanced Cancers
New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health.
Chemical Design Made Easier
Rice University scientists prepare elusive organocatalysts for drug and fine chemical synthesis.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
Giant Molecules Inhibit Ebola Infection
European researchers have designed a "giant" molecule formed by thirteen fullerenes covered by carbohydrates which, by blocking this receptor, are able to inhibit the cell infection by an artificial ebola virus model.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Fighting Pain with Ketamine
Researchers at the Texas A&M Health Science Center are using ketamine, a drug that already exists as an anesthetic, to treat pain.
Possible New Treatment for Neurodegenerative Diseases Found
Researchers at the University of Liverpool have found that a well-established anti-epileptic drug could also be used as a treatment for neurodegenerative diseases.
Breast Cancer Drug Beats Superbug
Tamoxifen helps white blood cells clear multidrug-resistant bacteria in lab and mouse studies.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos